SCHEMBL4382870

SCHEMBL4382870

C=CCN1CCN(C(=O)COc2cccc(Cl)c2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
POLB P06746 2/20 0.53
LMNA P02545 3/20 0.50
ALDH1A1 P00352 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
KDM4E B2RXH2 2/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 2/20 0.49
TSHR P16473 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
GAA P10253 2/20 0.46
MC4R P32245 1/20 0.46
MAPT P10636 1/20 0.45
ALOX12 P18054 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
SIGMAR1 Q99720 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636170 0.88 ALDH1A1 (0.44) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL4383577 0.81 ALDH1A1 (0.65) KMT2AMEN1LMNAALDH1A1L3MBTL1
SCHEMBL4380515 0.81 KMT2A (0.60) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL5061576 0.81 POLB (0.55) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL4378935 0.80 NPC1 (0.51) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL4379398 0.76 KDM4E (0.60) KMT2AMEN1POLBALDH1A1L3MBTL1
SCHEMBL27979631 0.76 MEN1 (0.88) KMT2AMEN1POLBALDH1A1L3MBTL1
SCHEMBL4382063 0.75 HTT (0.63) KMT2AMEN1POLBLMNAALDH1A1
SCHEMBL4377207 0.75 KDM4E (0.59) KMT2AMEN1POLBALDH1A1L3MBTL1
SCHEMBL4380513 0.75 FKBP1A (0.61) KMT2AMEN1POLBLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 KMT2A 295/4885MEN1 2570/4885POLB 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.